Page 165 - Aet News Today

The complaint alleges multiple violations of the Valentine Act, Ohio’s antitrust law, which prohibits price fixing, controlled sales and other agreements that restrain trade and hurt competition. David Yost, the attorney general decried the practices of PBMs saying that they hurt everyday Ohioans dependent on life-saving drugs like insulin.

Novartis is partnering with Bicycle Therapeutics to see if the biotech’s technology can be used to develop better, more targeted radiopharmaceuticals. The deal covers two targets that were not disclosed.

In an interview at the Vive conference in Nashville, Tennessee, Craig Richardville, Intermountain's chief digital and information officer outlined the three areas of priority for Intermountain Health for which technology can be leveraged. But when it comes to a major headache for CIOs, Richardville seems to suggest that a government-led all-hands-on-deck approach is what is needed.

In recent years, numerous biotech companies have adopted a portfolio approach with the promise that this strategy both diversifies risk and increases shots on goal. Though initially strong, the reception by the investor community is finally beginning to weaken.

Aneesh Chopra, president and co-founder of CareJourney, predicted accelerated enrollment in value-based care models in 2024 and 2025. He thinks this will greatly increase healthcare transparency for a few reasons, including making data more available and influencing more primary care doctors to act as health information fiduciaries on behalf of their patients.

As many as 25 million Americans over the age of five say they speak English “less than well” — that’s nearly a tenth of the country. Contrast that with the fact that nearly one third of American hospitals don’t provide interpreters to patients who speak little English, even though it is required by federal law. Only 13 states and Washington, D.C. provide reimbursements for the cost of medical interpreters through Medicaid.

Johnson & Johnson’s pullback from RSV research thins the pack of companies aiming to develop a vaccine for the pathogen. GSK and Pfizer have vaccines under FDA review and a shot from Moderna could soon follow.

Demand for alternative drug delivery methods has the potential to reshape therapeutic markets and improve clinical outcomes. New innovations, especially oral alternatives, are poised to drive broad changes across the entire sector.

Many health system technology executives have found that a strong digital transformation strategy requires sustained cross-department collaboration. At a recent conference panel, tech executives from UPMC and LifeBridge Health discussed why partnerships with the marketing department and analytics team are essential.

While alcohol-based hand sanitizers are very useful in settings where there is an increase in the transmission of pathogens (such as hospitals), there are no additional health benefits to habitual hand sanitizing unless a person doesn’t have access to running water.